Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Protein Discovered that Amplifies Cell Death

By Drug Discovery Trends Editor | January 15, 2009

Scientists at Albert Einstein College of Medicine of Yeshiva University have identified a small intracellular protein that helps cells commit suicide. The finding could lead to drugs for combating cancer and other diseases characterized by overproduction of cells. The research was led by the late Dennis Shields, Ph.D., a professor in Einstein’s Department of Developmental and Molecular Biology for 30 years, who died unexpectedly in December.

In response to stress or as a natural part of aging, many cells undergo programmed suicide, also known as apoptosis. Cancer cells often become immortal and dangerous by developing the ability to suppress apoptosis.

A decade ago apoptosis was thought to be directed solely by the nucleus and mitochondria of cells. Dr. Shields’ laboratory showed that a cellular organelle known as the Golgi apparatus also plays a role in apoptosis.

The Golgi package proteins and other substances made by cells and direct them to their destination within the cell. A protein called p115 is vital for maintaining the structure of the Golgi. In earlier research, Dr. Shields’ group demonstrated that the Golgi’s p115 protein splits into two pieces early in apoptosis and that the smaller of these protein fragments — 205 amino acids in length — helps to maintain the cell-suicide process.

In the present study, the Einstein researchers identified the smallest region of this p115 protein fragment that is required for apoptosis: a peptide of just 26 amino acids in length that exerts its apoptotic action by traveling to the nucleus.

Release Date: January 14, 2009
Source: Albert Einstein College of Medicine


Filed Under: Drug Discovery

 

Related Articles Read More >

Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE